Company profile
Kardigan, Inc.
NASDAQ: KARD · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenue
EA Score
——FH 35DQ —GM —SS 54
v0.1 · 35/100 weight · pillars only
↑ market scale, workforce scale · ↓ disclosure history, listing tenure
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$191.9M
Employees
241
as of 2026-08-01
Market cap
$1.9B
as of 2026-08-01
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$191.9M-$191.9M2025
Operating income-$201.8M-$201.8M2025
Total assets$390.9M$390.9M2025
Liabilities$641.3M$641.3M2025
Equity-$250.3M-$250.3M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Kardigan, Inc.’s revenue?
Kardigan, Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Amylyx Pharmaceuticals, Inc.51DSELLAS Life Sciences Group, Inc.50DRest Ez Inc.——Cullinan Therapeutics, Inc.50DDesign Therapeutics, Inc.55CMonopar Therapeutics Inc.59CNeighbors
Mercer →Key facts
CEOTassos Gianakakos
SectorHealthcare
IndustryBiotechnology
HeadquartersPrinceton, NJ
ExchangeNASDAQ: KARD
Employees241
IPO date2026-06-18
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.